Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epithelial-to-mesenchymal transition is a dynamic biological process where epithelial cells lose their polarity and cell-cell adhesion properties, acquiring migratory and invasive characteristics typical of mesenchymal cells. This transformation is orchestrated by key transcription factors such as Snail, Slug, Twist, ZEB1/2—which repress epithelial markers like E-cadherin while activating mesenchymal markers including vimentin and fibronectin. EMT plays essential roles in embryonic development (Type 1), tissue regeneration/wound healing/fibrosis (Type 2), and cancer progression/metastasis/chemoresistance (Type 3). The process is regulated by signaling pathways involving TGF-beta, FGF, Wnt/beta-catenin among others. While it is not itself a molecular target such as an enzyme or receptor but rather a complex program involving many molecules—therapeutic strategies often aim to modulate the activity of its key regulators to prevent pathological outcomes like tumor metastasis or organ fibrosis[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epithelial-to-mesenchymal transition process (EMT).